BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic IPSC Derived Cell Therapy Platform Across Multiple Indications
BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic IPSC Derived Cell Therapy Platform Across Multiple Indications
- BrightPath to receive non-exclusive rights to Artisan's STAR-CRISPR editing platform to accelerate development of BrightPath's invariant natural killer T (iNKT) cells
- Artisan to receive an upfront payment and research milestones, plus license fees, development milestones, net sales milestones, and royalty on future products
- BrightPath 將獲得 Artisan 的 STAR-CRISPR 編輯平台的非專有版權，以加速 BrightPath 不變自然殺手 T (inkT) 細胞的開發
- Artisan 將獲得預付款和研究里程碑，以及許可費、開發里程碑、淨銷售里程碑和未來產品的特許權使用費
TOKYO and DENVER, May 2, 2023 /PRNewswire/ -- BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc, a precision genome engineering and drug discovery company, today announced they have signed a research and licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies to clinic.
東京 和 丹佛， 2023年5月2日 /PRNewswire/ — BrightPath Biotherapeutics Co., Ltd.（TYO：4594），一家臨床階段的生物技術公司，專注於開發源自不變自然殺傷劑T（InkT）細胞的細胞療法，以及Artisan Bio。精密基因組工程和藥物發現公司Inc今天宣佈，他們已經簽署了一項研究和許可協議，以加速BrightPath的下一代InkT細胞療法進入臨床階段。
"This collaboration with Artisan provides BrightPath with the potential to create highly engineered allogeneic iNKT cellular therapy programs for a range of indications, including solid tumors," said Kenichi Nagai, BrightPath CEO. "Artisan's STAR-CRISPR system, and their leading editing efficiencies in iPSC cells, will enable BrightPath's iNKT cell therapies to solve the persistence and efficacy problems faced by first generation allogeneic CAR-T programs."
他說：“與Artisan的合作使BrightPath有可能爲包括實體瘤在內的一系列適應症創建高度工程化的異體InKT細胞療法項目。” 永井健一，BrightPath 首席執行官。“Artisan的STAR-CRISPR系統及其在iPSC細胞中的領先編輯效率將使BrightPath的InkT細胞療法能夠解決第一代異體CAR-T項目面臨的持久性和療效問題。”
"We are excited for the BrightPath collaboration and the development of highly engineered iPS cells for cell therapy," said Ryan Gill, Artisan Bio CEO. "The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimized guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling."
他說：“我們對BrightPath的合作以及用於細胞療法的高度工程化iPS細胞的開發感到興奮。” 瑞安·吉爾，Artisan Bio 首席執行官。“BrightPath產品將建立在我們領先的STAR-CRISPR平台、高度優化的異基因和專有靶基因指南以及我們嚴格的脫靶安全分析的基礎上。”
Under this agreement, BrightPath will pay Artisan an upfront payment and research milestones for the development of CRISPR guides for the editing of BrightPath's iNKT cells. BrightPath has the right to a commercial license for the STAR-CRISPR guides and nuclease for a license fee plus development milestones, sales milestones, and a royalty on future products.
根據該協議，BrightPath將向Artisan支付一筆預付款，並支付研究里程碑，用於開發用於編輯BrightPath的InkT細胞的CRISPR指南。BrightPath有權獲得STAR-CRISPR指南和核酸酶的商業許可，但需支付許可費，外加開發里程碑、銷售里程碑和未來產品的特許權使用費。
About BrightPath:
BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drugs targeted at cancer specific neoantigens. For more information, visit .
關於 BrightPath：
BrightPath是一家臨床階段的生物製藥公司，專注於開發新的癌症免疫療法，以改變傳統標準療法無法治療的難治性或進行性癌症的癌症治療方法。BrightPath積極參與開發目前正在進行臨床試驗的細胞療法、免疫調節抗體和針對癌症特異性新抗原的新藥。欲了解更多信息，請訪問 。
About Artisan:
Artisan Bio is a world-leader in CRISPR genome engineering technology and provides drug developers with advanced genome engineering and drug discovery tools for the research and commercialization of cell and gene therapies, including companies such as Takeda and Cabaletta Bio. Artisan's proprietary STAR-CRISPR gene editing platform delivers leading editing efficiencies in multiple cell types including iPSC and T-cells, and is available through non-exclusive licenses. Artisan's SyionAI platform utilizes high-throughput CRISPR editing for novel drug discovery. For more information, visit .
關於 Artisan：
Artisan Bio是CRISPR基因組工程技術的全球領導者，爲藥物開發人員提供先進的基因組工程和藥物發現工具，用於細胞和基因療法的研究和商業化，包括武田和Cabaletta Bio等公司。Artisan 專有的 STAR-CRISPR 基因編輯平台可在包括 iPSC 和 T 細胞在內的多種細胞類型中提供領先的編輯效率，並且可通過非獨家許可獲得。Artisan 的 SyionAI 平台利用高通量 CRISPR 編輯來發現新藥。欲了解更多信息，請訪問 。
SOURCE Artisan Bio
來源 Artisan Bio
譯文內容由第三人軟體翻譯。